Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN and CNCI to Establish Cervical Cancer Screening Program in Kolkata

Published: Monday, April 27, 2009
Last Updated: Monday, April 27, 2009
Bookmark and Share
The initiative will be conducted over 5 years and is expected to reach 50,000 women.

QIAGEN and the Chittaranjan National Cancer Institute (CNCI) have announced a collaboration to establish the first large-scale cervical cancer screening program for women in Kolkata, India.

QIAGEN will provide its diagnostic tests for the human papillomavirus (HPV) - the primary cause of cervical cancer. CNCI will conduct the screening and provide appropriate treatment as needed. Financial terms were not disclosed.

The “QIAGENcares Kolkata Project” will use QIAGEN’s hybrid capture 2 (hc2) HPV DNA testing technology (also known as the digene® HPV Test) to screen women for cancer-causing types of HPV to identify those with or at risk for developing cervical cancer.

Participating women will also be screened using VIA (visual inspection with acetic acid) as per the Indian National Guidelines for Cervical Screening. Screening will take place at community-based mobile field clinics in the villages neighboring Kolkata.

Women found to have cervical cancer or pre-cancer will be immediately treated at the field clinic – a process referred to as “screen and treat” – or referred to the CNCI for follow up.

The project also includes educational campaigns to raise awareness about HPV, cervical cancer, and other women’s health issues. The initiative will be conducted over 5 years and is expected to reach 50,000 women.

“This project is a great demonstration of how our advanced screening solutions can bring state of the art healthcare to women in all regions of the globe. Kolkata, India is a particularly fitting location to launch this project as India has the world’s highest incidence rate of cervical cancer. We believe that launching this project can play a role in helping to change those statistics,” said Mr. Peer Schatz, CEO of QIAGEN.

“Through the QIAGENcares Kolkata collaboration we will increase awareness about cervical cancer prevention and make screening more accessible, two vital ingredients in the effort to reduce cervical cancer rates. Also, we are looking forward to demonstrating the combination of cost effectiveness and enormous value for healthcare that QIAGEN’s state of the art cervical cancer screening solutions can bring to a setting such as the one in Kolkata.”

The Kolkata screening project is a part of QIAGENcares, the company’s corporate social responsibility program focused on improving health by providing access to screening methods for infectious diseases in emerging and developing countries.

“We are pleased to work with QIAGEN on this cervical cancer screening project. We here at the CNCI see first-hand how serious a threat cervical cancer is to the health of women locally and to Indian society as a whole. We hope this collaboration will help raise awareness of the issue and set an example for other screening projects in the future,” said Dr. Jaydip Biswas, Director, CNCI.

The cervical cancer screening program is launched at the opening ceremony of the 2009 Asia-Oceania Research Organization on Genital Infections and Neoplasia (AOGIN) conference in Kolkata on April 25-26. The first women are expected to be screened in June.

QIAGEN’s HPV test platform – known as the digene HPV Test – uses advanced molecular diagnostic technologies to identify the presence of the genetic code (DNA) of 13 high-risk, cancer-causing types of HPV.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Joins Consortium to Map Microbial Genomes
The project will use QIAGEN sample technologies and library preparation workflows to extract and prepare genomic materials for analysis.
Saturday, July 02, 2016
Qiagen and 10x Genomics to Enter Into Co-Marketing and Co-Development Collaboration
Company has announced that the multi-phase collaboration to advance next-generation sequencing, single-cell biology, and bioinformatics Sample to Insight solutions.
Wednesday, February 17, 2016
QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!